Find information on thousands of medical conditions and prescription drugs.

Valganciclovir

Valganciclovir hydrochloride (Valcyte®) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Administration

Orally, available in 450 mg pink tablets. Dosing is calculated to provide appropriate doses of ganciclovir; 900 mg of valganciclovir orally every 12 hours is equivalent to 5 mg per kilogram of body weight of intravenous ganciclovir, also every 12 hours.

Pharmacokinetics

  1. Oral bioavailability is approximately 60%. Fatty foods significantly increase the bioavailability and the peak level in the serum.
  2. It takes about 2 hours to reach maximum concentrations in the serum.
  3. Valganciclovir is eliminated as ganciclovir in the urine, with a half-life of about 4 hours in people with normal kidney function.

Side effects

  • Blood: neutropenia, anemia, low platelets. Myelosuppression is one of the main side effects that may limit prolonged use of valganciclovir.
  • Gastrointestinal: diarrhea, nausea, vomiting, abdominal pain.
  • Central nervous system: fever, headache, insomnia, paresthesia, and peripheral neuropathy.
  • Ocular: retinal detachment

Read more at Wikipedia.org


[List your site here Free!]


Stability of valganciclovir in an extemporaneously compounded oral liquid
From International Journal of Pharmaceutical Compounding, 3/1/03 by Foy, Elizabeth

Stability of valganciclovir in an extemporaneously compounded oral liquid.

Anaizi NH, Dentinger PJ, Swenson CF Am J Health Syst Pharm 2002;59:1267-- 1270.

The procedure for compounding an oral suspension of valganciclovir 90 mg/mL from tablets in a cherry-chocolate syrup vehicle is described. The authors' stability testing indicates that this oral suspension retains more than 90% of the initial valganciclovir concentration when stored in amber polyethylene terephthalate bottles in a refrigerator at 2 deg C to 8 deg C for 125 days.

Copyright International Journal of Pharmaceutical Compounding Mar/Apr 2003
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Valganciclovir
Home Contact Resources Exchange Links ebay